Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy as perioperative treatment in resectable non-small cell lung cancer
ChiCTR2300074485Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoints: Pathological complete response rate (pCR) and Event-free survival (EFS). Started Aug 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300074485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074485.